Larimar Therapeutics Incis A Clinical Stage Biotechnology Company Located In Bala Cynwydpennsylvaniathe Company Focuses On Developing Treatments For Complex Rare Diseaseswith An Initial Emphasis On Friedreichae S Ataxiaa Rare Genetic Disorderutilizing A Novel Cell Penetrating Peptidecpptechnology Platformlarimar Aims To Deliver Therapeutic Molecules Across Cell Membranes To Address Intracellular Deficiencies Associated With Various Rare Diseases The Company S Lead Product Candidate Is Nomlabofuspa Recombinant Fusion Protein Designed To Transport Frataxinan Essential Proteinto The Mitochondria Of Patients With Friedreich S Ataxiathis Product Is Currently Undergoing A Phase 2 Clinical Triallarimar S Cpp Technology Has The Potential To Extend Its Applications To Other Orphan Diseases Characterized By Intracellular Protein Deficienciesthe Company Is Led By Ceo Carole Ben Maimon And Employs Around 65 People
